Evidence map›Paper›PMID 41038866›Full record

ArticleSignal transduction and targeted therapy2025

Retinol Binding Protein 4 reactivates latent HIV-1 by triggering canonical NF-κB, JAK/STAT5 and JNK signalling.

Chiara Pastorio, Khumoekae Richard, Shariq Usmani, Ann-Kathrin Kissmann, Grigory Bolotnikov, Guillermo Gosálbez, Manuel Hayn, Lennart Koepke, Alina Sauertnik, Andrea Preising and 19 more

Abstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Chiara Pastorio *Institute of Molecular Virology, Ulm University Medical Centre, Ulm, Germany.ORCID 0000-0002-4745-3678
Khumoekae Richard *HIV Cure and Viral Diseases Center, The Wistar Institute, Philadelphia, PA, USA.
Shariq Usmani *Institute of Molecular Virology, Ulm University Medical Centre, Ulm, Germany.
Ann-Kathrin Kissmann *Institute of Pharmaceutical Biotechnology, Ulm University, Ulm, Germany.
Grigory BolotnikovInstitute of Pharmaceutical Biotechnology, Ulm University, Ulm, Germany.
Guillermo GosálbezInstitute of Molecular Virology, Ulm University Medical Centre, Ulm, Germany.
Manuel HaynInstitute of Molecular Virology, Ulm University Medical Centre, Ulm, Germany.
Lennart KoepkeInstitute of Molecular Virology, Ulm University Medical Centre, Ulm, Germany.
Alina SauertnikInstitute of Molecular Virology, Ulm University Medical Centre, Ulm, Germany.
Andrea PreisingInstitute of Molecular Virology, Ulm University Medical Centre, Ulm, Germany.
Nico PreisingCore Facility Functional Peptidomics (CFP), Ulm University Medical Center, Ulm, Germany.
Ludger StändkerCore Facility Functional Peptidomics (CFP), Ulm University Medical Center, Ulm, Germany.
Matthew FairHIV Cure and Viral Diseases Center, The Wistar Institute, Philadelphia, PA, USA.
Jessicamarie MorrisHIV Cure and Viral Diseases Center, The Wistar Institute, Philadelphia, PA, USA.
Emmanouil PapasavvasHIV Cure and Viral Diseases Center, The Wistar Institute, Philadelphia, PA, USA.
Qin LiuHIV Cure and Viral Diseases Center, The Wistar Institute, Philadelphia, PA, USA.
Honghong SunDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, USA.
Armando RodríguezCore Facility Functional Peptidomics (CFP), Ulm University Medical Center, Ulm, Germany.ORCID 0000-0001-5921-3770
Karam MounzerHIV Cure and Viral Diseases Center, The Wistar Institute, Philadelphia, PA, USA.
Sebastian WieseCore Unit Mass Spectrometry and Proteomics (CUMP), Ulm University Medical Center, Ulm, Germany.
Pablo TebasDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, USA.ORCID 0000-0001-5345-7942
Yangzhu DuDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, USA.
Gregory M LairdAccelevirDx, Baltimore, MD, USA.
Markus JaritzResearch Institute of Molecular Pathology, Vienna BioCenter, Vienna, Austria.ORCID 0000-0002-9326-2047
Frank RosenauInstitute of Pharmaceutical Biotechnology, Ulm University, Ulm, Germany.
Moritz M GaidtResearch Institute of Molecular Pathology, Vienna BioCenter, Vienna, Austria.
Konstantin M J SparrerInstitute of Molecular Virology, Ulm University Medical Centre, Ulm, Germany.ORCID 0000-0002-8682-1779
Luis J MontanerHIV Cure and Viral Diseases Center, The Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0001-5799-6759
Frank KirchhoffInstitute of Molecular Virology, Ulm University Medical Centre, Ulm, Germany. frank.kirchhoff@uni-ulm.de.ORCID 0000-0002-7052-2360

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ronald G Collman · 1999 to 2026
$78.6M
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7M
Centralized Resource to Accurately Quantify Latent and Expressed HIV ReservoirsU24AI143502 · NIAID · ACCELEVIR DIAGNOSTICS, LLC · PI LAIRD, GREGORY MICHAEL, MARTIN, ALBINE · 2020 to 2024
$4.9M
Centralized Resource to Accurately Quantify Latent and Expressed HIVReservoirsR24AI143502 · NIAID · ACCELEVIR DIAGNOSTICS, LLC · PI Gregory Michael Laird, Albine Martin · 2025 to 2026
$2.1M
Deutsche Forschungsgemeinschaft (German Research Foundation) CRC 1279NCI NIH HHS P30 CA016520NIAID NIH HHS P30 AI045008NIAID NIH HHS R24 AI143502NIAID NIH HHS U24 AI143502NIAID NIH HHS UM1 AI164570
6 · The paper itself

Abstract

Reactivation of the latent viral reservoirs is crucial for a cure of HIV/AIDS. However, current latency reversing agents are inefficient, and the endogenous factors that have the potential to reactivate HIV in vivo remain poorly understood. To identify natural activators of latent HIV-1, we screened a comprehensive peptide/protein library derived from human hemofiltrate, representing the entire blood peptidome, using J-Lat cell lines harboring transcriptionally silent HIV-1 GFP reporter viruses. Fractions potently reactivating HIV-1 from latency contained human Retinol Binding Protein 4 (RBP4), the carrier of retinol (Vitamin A). We found that retinol-bound holo-RBP4 but not retinol-free apo-RBP4 strongly reactivates HIV-1 in a variety of latently infected T cell lines. Functional analyses indicate that this reactivation involves activation of the canonical NF-κB pathway and is strengthened by JAK/STAT5 and JNK signalling but does not require retinoic acid production. High levels of RBP4 were detected in plasma from both healthy individuals and people living with HIV-1. Physiological concentrations of RBP4 induced significant viral reactivation in latently infected cells from individuals on long-term antiretroviral therapy with undetectable viral loads. As a potent natural HIV-1 latency-reversing agent, RBP4 offers a novel approach to activating the latent reservoirs and bringing us closer to a cure.

Indexed as

HIV-1HIV InfectionsNF-kappa BRetinol-Binding Proteins, PlasmaSTAT5 Transcription FactorVirus ActivationVirus LatencyHumansJanus KinasesMAP Kinase Signaling SystemJanus KinasesNF-kappa BRBP4 protein, humanRetinol-Binding Proteins, PlasmaSTAT5 Transcription Factor

Identifiers

PMID41038866
PMCPMC12491451

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.